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Summary: Fibrinogen is considered to be a strong predictor and independent factor of cardiovascular diseases.
The data presented here describe the baseline measurements of fibrinogen in 1008 apparently healthy subjects,
aged 4—60 years and their relationship to age, sex, body weight, smoking, alcohol, and use of oral
contraceptives. Pearson's correlations and a linear multiple regression model were used.
Plasma fibrinogen was measured kinetically in a photometer, the Behring Chromotimer, using the CTS-
fibrinogen method.
There were neither statistical difference between girls and boys aged 4—20 years nor correlation with variables
related to cardiovascular diseases. In adults, we found an increase of plasma fibrinogen concentration with
age and no statistical difference between men and women, except in subjects aged 40 — 50 years. There was a
positive correlation between fibrinogen and ponderal index. In women aged 20 — 30, 30—40, 40 — 50 and
50 — 60 years, the mean fibrinogen concentrations increased of 0.009,0.021, 0.010 and 0.015 g/1 for one percent
of overweight, in each subgroup respectively.
In women aged 20 — 30 years using oral contraceptives, the mean fibrinogen concentration was 0.19 g/1 higher
than in women not using oral contraceptives.
The smoking effect was observed only in 30 — 40 year-old men. Each cigarette smoked per day increases of
the mean fibrinogen by 0.35 g/1 after standardization for ponderal index and alcohol consumption. Alcohol
consumption was negatively correlated to plasma fibrinogen in subjects 30—40 years old. In women, l g of
alcohol per day induces a 0.008 g/1 decrease in the mean fibrinogen while in men the decrease is 0.004 g/1.
A correlation was found between fibrinogen and serum cholesterol (p < 0.001 and p < 0.01 for men and
women, respectively) and fibrinogen and triacylglycerols (p < 0.05 and p < 0.001 for men and women,
respectively). The known risk factors for cardiovascular diseases explained at most 15% of the total variance
in fibrinogen concentrations among the studied population. Finally, reference limits according to age and sex
are provided.
Introduction . , . . . , .
tion, and its concentration in plasma increases in
Plasma fibrinogen, which is synthesized in the liver, many non-specific situations. Fibrinogen and fibrin
is an essential blood coagulation factor. Its transfor- are also profoundly involved in atherogenesis (1, 2).
mation into fibrin contributes to the formation of As fibrinogen is involved in arteriosclerotic diseases
stable clots, and it is an essential cofactor in platelet and thrombosis, it may be a good predictor of car-
aggregation. It increases plasma and blood viscosity diovascular diseases and major peripheral vascular
and causes the aggregation of red cells, all of which diseases, as well as being an independent factor in
reduce blood flow. It also plays a role in inflamma- these diseases. Various prospective studies (2 — 9),
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case-control studies (10, 11) and prevalence studies
(12, 13) have shown that fibrinogen increases in sub-
jects with cardiovascular diseases. The epidemiologi-
cal Northwick Park heart study, in particular, showed
that a fibrinogen value of one standard deviation
(about 0.6 g/1) above the mean (2.9 g/1) was associated
with an 84% increase in the risk of an episode of
ischaemic heart disease within 5 years (2). These data
and the studies of Balleisen et al. (14, 15) associating
fibrinogen with known risk factors of atherosclerosis
led us to establish the reference limits for plasma
fibrinogen in supposedly healthy subjects attending a
preventive medicine centre for health screening.
We looked for any variations in fibrinogen concen-
tration associated with certain cardiovascular risk fac-
tors (such as use of oral contraceptives, consumption
of alcohol, smoking, ponderal index, blood pressure
and serum cholesterol and triacylglycerols), studied
the relationships between fibrinogen and these quan-
tities and tried to account for the fibrinogen variation
by means of a step wise linear multiple regression.
Materials and Methods
Participants
We studied 1008 apparently healthy subjects (510 men and 498
women) aged 4—60 years. Subjects suffering from an inflam-
matory reaction were identified and excluded if the erythrocyte
sedimentation rate was > 20 mm/h or if the C-reactive protein
concentration measured by the immunolatex method in a Behr-
ing Nephelometer Analyser was > 10 mg/1. None of the sub-
jects was using any medication, except 109 women, aged 20 —
30 years and 40 — 50 years, who were taking oral contraceptive
drugs. No women aged 30—40 years taking oral contraceptives
were selected.
Methods
Blood specimens were obtained by venipuncture from the cub-
ital vein of fasting, supine subjects between 0800 and 0900 hr.
Serum and citrated plasma were aliquoted and stored at
—20 °C, and analysed within 8 days of collection.
Plasma fibrinogen was measured kinetically in a photometer,
the Behring Chromotimer. Citrated plasma was coagulated by
the addition of a relatively large amount of thrombin. In an
optimized buffer the increase in absorbance is directly propor-
tional to the fibrinogen concentration. The results are given in
grams per litre. The instrument and reagents (CTS-Fibrinogen
Reagent) are manufactured by Behring Diagnostic Rueil-Mal-
maison, France. Day-to-day controls were tested using CTS-
control plasma (Behring). The within-run variation was 5.5%
(n = 21, m ± SD = 2.00 ± 0.11 g/1).
To evaluate preanalytical variation, we studied samples stored
at 4 °C for 24 or 48 hours, and at -20 °C for 1, 2 or 8 days.
There was no statistically significant difference between plasma
fibrinogen values measured at day 0 and those measured after
1 or 2 days storage at 4 °C or after 1, 2 or 8 days storage at
— 20 °C. These results are in agreement with the recommen-
dations of the National Committee for Clinical Laboratory
Standards (NCCLS), which permit citrated plasma to be frozen
and stored at -20 °C for more than 8 days (16).
Serum cholesterol and triacylglycerols were measured by en-
zymatic methods [CHOD-PAP and GPO-PAP, respectively
(Merck, Darmstadt 1, Germany)] on an Olympus Au 5010
(Olympus Biologie, 94150 Rungis, France).
Height in stocking feet and weight in light clothing were meas-
ured. The ponderal index was calculated according to the Lor-
entz formula (17, 18): (measured weight/theoretical ideal
weight) χ 100; the theoretical ideal weight (kg) depending on
the height (H cm) was calculated from the following equations:
(H - 100)-(H - 150)/4 for men; and (H - 105)-(H -
150)/4, for women.
Systolic and diastolic blood pressures were measured using a
mercury sphygmomanometer with appropriate-sized cuffs on
the left arm of supine subjects after a five minute test. One
reading was taken and used for analysis.
Smoking habits and alcohol intake were known from a ques-
tionnaire which the patients answered. Subjects smoking less
than 5 cigarettes (or pipe or cigar equivalents) per day or
drinking less than 22 g of alcohol daily were considered as non-
smokers or non-drinkers.
Statistical evaluation
Student's t-test and Bartletfs test were used to determine dif-
ferences in mean values and to analyse the variances, respec-
tively; Pearson's correlation was used to test the linear rela-
tionship between fibrinogen and the following variables: age,
weight, ponderal index, systolic and diastolic blood pressure,
alcohol (g/day) and cigarette (g/day) consumption, use of oral
contraceptives and serum total cholesterol and triacylglycerols.
A linear multiple regression model was used to test the inde-
pendent influence of these variables on fibrinogen concentration
(19).
Results
Population distribution
A %2-test showed that the hypothesis of a Gaussian
distribution of plasma fibrinogen within each age
group (4-14, 14-20, 20-30, 30-40, 40-50 and
50 — 60) and each sex was acceptable.
Age and sex
The Student's t-test shows that there was no statistical
difference between the sexes except in subjects aged
40-50 years [mean ± SD for men = 2.99 ± 0.59 g/1
(n = 125) versus 2.81 ± 0.50 g/1 for women (n = 90),
p = 0.017]. The analysis of variances between each
age group (for men or for women) shows that there
was no statistical difference between the variances,
but there were statistical differences between the
means (for men F = 6.761, p < 0.001; for women
F = 3.829, p < 0.003). Fibrinogen was higher in chil-
dren and adolescents than in adults aged 20 — 30
years. There were statistically significant differences
between children (both girls and boys) aged 4—14
years and adults aged 20 — 30 years, for example: boys
(n = 54), mean + SD = 3.07 ± 0.57 g/1; men
(n = 109), 2.65 ± 0.52 g/l; p < 0.001. From age 30,
plasma fibrinogen increased steadily in both women
and men.
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Using fibrinogen concentration as the dependent var-
iable, a stepwise multiple linear regression model was
performed for men and women aged 4 — 14, 14 — 20,
20-30, 30-40, 40-50 and 50-60 years.
In both male and female children, no tested variable
affected the fibrinogen concentration.
Smoking
In adults, a significant effect of smoking appeared
only in men aged 30 — 40 years. Each cigarette smoked
per day increased the mean fibrinogen by 0.35 g/1
after standardization for ponderal index and alcohol
consumption. In men aged 20 — 50 years smoking
more than 10 cigarettes per day, the fibrinogen con-
centration was higher (+ 0.19 g/1) than in non-smok-
ers. Thus, fibrinogen varied from 2.785 g/l ± 0.564
(mean + SD) in non-smokers (n = 163) to 2.974
± 0.615 (mean + SD) in men (n = 119) smoking
more than 10 cigarettes per day.
fibrinogen concentrations were 2.707 g/1 (± 0.444) in
75 women without oral contraception, aged 20 — 30
years with a ponderal index between 70 — 130, and
2.921 g/1 (+ 0.564) in 88 women of the same age and
using oral contraceptives. In the women 40 — 50 years
old, too few women were taking oral contraceptives,
so that the results were not statistically significant.
Correlations and multivariate analysis
The table 1 shows the coefficients of correlation be-
tween fibrinogen and the biological variables associ-
ated with cardiovascular risk in subjects aged 20 — 60
years. The plasma fibrinogen concentration was po-
sitively correlated with age, weight, ponderal index,
and serum total cholesterol and triacylglycerols in
subjects of both sexes, with systolic and diastolic
blood pressure in women only, and with cigarette
consumption in men; it was negatively correlated with
alcohol consumption in women.
Alcohol consumption
The effects of alcohol consumption were studied in
subjects 30 — 40 years old. In women, l g of alcohol
per day induced a 0.008 g/1 decrease in the mean
fibrinogen concentration after standardization for
weight and use of oral contraceptives. The fibrinogen
varied from 2.936 g/1 ± 0.415 (mean ± SD) in women
who drank less than 22 g of alcohol per day (n = 44)
to 2.670 g/1 ± 0.347 in women (n = 8) drinking more
than 22 g/d of alcohol. In men, after standardization
for ponderal index and cigarette consumption, the
decrease was 0.004 g/1 for l g of alcohol per day.
Overweight
Regression analysis showed that the fibrinogen con-
centration increased by 0.1, 0.21, 0.1 and 0.15 g/1 per
10% overweight for women aged 20-30, 30-40,
40 — 50 and 50 — 60 years, respectively. In men, over-
weight affected the fibrinogen concentration only in
subjects aged 30—40 and 50 — 60 years (increases of
0.10 and 0.14 g/1, respectively, per 10% of over-
weight).
Tab. 1. Correlation coefficients between plasma fibrinogen and
selected cardiovascular disease risk factors in subjects
aged 20 — 60 years
Men Women
Age
Weight
Systolic blood pressure
Diastolic blood pressure
Ponderal index
Alcohol consumption
Cigarettes consumption
Oral contraceptives
Serum cholesterol
Serum triacylglycerols
0.275***
0.144***
NS
NS
0.226***
NS
0.100*
—
0.209***
0.116*
0.139**
0.284***
0.130*
0.123*
0.337***
-0.102*
NS
NS
0.156**
0.228***
p < 0.001; ** p < 0.01; * p < 0.05, NS not significant
The results of the stepwise multiple linear regression
model performed for adults aged 20 — 60 years are
summarized in table 2. The regression coefficient cor-
responds to the change in fibrinogen concentration
associated with one unit change in the variable; this
accounts for 13.9% and 15% of the total variance in
men and women, respectively.
Use of oral contraceptives
The influence of oral contraceptives on the fibrinogen
concentration was evaluated only in women aged 20 —
30 and 40 — 50 years. In the younger group, the mean
fibrinogen concentration of women taking oral con-
traceptives was significantly (0.19 g/1) higher, weight
for weight, than in the women not taking them. The
Reference limits
Reference limits were established according to the
recommendations of the International Federation of
Clinical Chemistry (20) and the Societe Frangaise de
Biologie Clinique (21), using the following exclusion
and partition criteria. Exclusion criteria: non-fasting
state, overweight (ponderal index > 120), use of drugs
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Tab. 2. Results of a step wise multiple regression of plasma fibrinogen (g/1) in relation to other cardiovascular risk factors in
subjects aged 20—60 years
Men (n = 378) Women (n = 377)
Variables Regression coefficient (SE) Regression coefficient (SE)
Age (years)
Systolic blood pressure mmHg
Diastolic blood pressure mmHg
Ponderal Index (%)
Alcohol consumption (g/day)
Cigarettes consumption (g/day)
Use of contraceptives
Serum cholesterol (mmol/1)
Serum triacylglycerols (mmol/1)
0.0132 (0.0029)*
0.0049 (0.0021)*
-0.0023 (0.0007)**
0.0061 (0.0018)***
0.0493 (0.0221)*
Intercept: 1.543
R2: 0.139
0.0092 (0.0016)***
-0.0060 (0.0020)**
0.1506 (0.0487)*
Intercept: 1.792
R2: 0.150
p < 0.001; ** p < 0.01; * p < 0.05; -: not significant; SE: standard error
and/or oral contraceptives, cigarette consumption
more than 5 per day and alcohol intake higher than
22 g per day. Partition criteria: age, sex.
The estimates of percentiles 5 and 95, assuming a
Gaussian distribution, are given in table 3.
Discussion
Fibrinogen concentrations were higher in children and
adolescents than in adults aged 20 — 30 years. Al-
though published reports offer no explanation of this
difference, it may be related to growth.
Like other authors (14, 22, 23), we found an increase
of fibrinogen concentration with age in adults but no
statistical difference between the sexes. Lee et al. (9),
in contrast, found higher fibrinogen concentrations
in women than in men (p < 0.001).
The positive relationships between fibrinogen concen-
trations and the body-weight or ponderal index were
statistically significant in both males and females, as
in the Northwick Park study (22) and the Münster
arteriosclerosis study (14), in which skinfold thickness
or the Broca index, respectively, was used.
Women aged 20 — 30 years taking oral contraceptives
had higher fibrinogen concentrations than those not
taking them (p < 0.01). The difference between those
using and not using oral contraceptives disappeared
in women aged 40 — 50 years, and we did not observe
any relationship between fibrinogen concentration
and oral contraceptive use in women aged 20 — 60
years considered as a single group. The small number
of subjects might explain these discrepancies, because
epidemiological studies (14, 24, 25) have shown that
the use of oral contraceptives greatly increases the
fibrinogen concentration: from 0.18 (14) to 0.35 (24)
or 0.4 g/1 (25). The use of oral contraceptives induced
not only an increase of fibrinogen concentration but
also an increase of factors VII and X and a decrease
of antithrombin III concentrations. These changes,
together with the rise of triacylglycerols and blood
pressure would all be expected to favour thrombosis
(24).
The biological variability of fibrinogen in healthy
subjects during one day was estimated to be 3.5%
but it may attain 13.0%. Over 6 months, this intra-
individual variability reached 10% to 18.9% (26).
Other authors (27) have reported intra-individual var-
Tab. 3. Reference limits of plasma fibrinogen (g/1) according to age and sex.
Number of patients (n), mean (x), standard deviation (SD) and estimated percentiles (5 and 95) are given
Age (years)
Men Women
SD Percentiles SD
95
Percentiles
95
4-14
14-20
20-30
30-40
40-50
50-60
54
55
109
33
125
51
3.07
2.85
2.65
2.77
2.99
2.89
0.57
0.46
0.52
0.49
0.59
0.47
2.13
2.09
1.80
1.96
2.02
2.12
4.01
3.61
3.50
3.58
3.96
3.66
52
56
75
43
90
41
2.94
2.94
2.71
2.85
2.81
3.05
0.46
0.45
0.44
0.37
0.50
0.46
2.18
2.20
1.99
2.24
1.99
2.29
3.70
3.68
3.43
3.46
3.63
3.81
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iation of 26% or 41% over 5 years. Thus "the capa-
bility for detecting a difference between two groups
will depend to a large extent on its magnitude. The
smaller this is the larger the number of observations
required for its demonstration" (27).
In our study, a slight effect of smoking on the fibri-
nogen concentration was seen only in men. These
findings are consistent with those of other authors
(7 — 9, 14, 23, 28), who, however, also found an effect
in women. There is some evidence of a dose-response
effect of smoking on fibrinogen (9). The smoking
cessation and the adoption or resumption of smoking
were associated with a decrease or an increase, re-
spectively, of about 0.15 g/1 in plasma fibrinogen.
These changes would lower or raise the risk of is-
chaemic heart disease by about 20% (29).
In our study, a slight negative correlation between
alcohol intake and fibrinogen was found only in
women. However, a linear multiple regression analysis
showed a significant negative effect of alcohol in both
sexes (p < 0.05). Other authors (9, 24) have found
that non-drinkers of both sexes have higher fibrinogen
concentrations than drinkers (p < 0.001), even after
standardization for smoking. In contrast, the M nster
arteriosclerosis study did not show a significant cor-
relation (14).
The plasma fibrinogen concentration is correlated
with other risk factors of cardiovascular disease, such
as blood pressure and serum total cholesterol and
triacylglycerols. Our results showed a positive rela-
tionship between fibrinogen and blood pressure, in
women only, as in other studies (9,15). Some authors
(4, 6 — 8), however, have found a correlation in men
too (p < 0.05 to ρ < 0.001). Like others (9, 15), we
have also seen a positive relationship between fibri-
nogen and cholesterol or triacylglycerols. Neverthe-
less, in the stepwise multiple regression analysis of
plasma fibrinogen in relation to other variables, serum
cholesterol appears only in men (p < 0.05) and tria-
cylglycerols in women (p < 0.01), all aged 20 — 60
years.
Recently, Landin et al. (30) found that fibrinogen
concentrations in hypertensive patients were 18%
higher (p < 0.05) than in normotensive subjects of
the same age, bodyweight and height. This increase
was associated with increased cholesterol, triacylgly-
cerols, glucose, plasma insulin, plasminogen activator
inhibitor (PAI-1) (30), globulin, albumin, total protein
and plasma viscosity (31). Stone & Thorp's prospec-
tive study (6) of 297 men aged 40 — 69 years observed
for a mean period of 7 years showed that in men with
high cholesterol or high systolic blood pressure, the
incidence of heart attacks was respectively 6 times
and 12 times greater in those with high plasma fibri-
nogen concentrations (> 3.5 g/1) than in those with
low fibrinogen concentration.
The results of the multivariate analysis are essentially
the same in men and in women and do not account
for the sex differences in cardiovascular morbidity.
Only a small percentage of the fibrinogen variation
can be explained by the factors previously cited. Other
factors may have very important effects.
Sex-related factors such as pregnancy or postmeno-
pausal status induce large fibrinogen variations. It
increases by 60% until the 37th week of gestation,
then decreases at 8 weeks postpartum (p < 0.05) (37).
In postmenopausal women, plasma fibrinogen is
higher than in premenopausal women of the same age
(p < 0.01) (9).
Genetic variations were described by Humphries et al.
(32), who found mean fibrinogen concentrations of
2.74, 3.69 and 2.98 g/1 in subjects with genotypes
BiBl9 B2B2 and B^ respectively. Polymorphism ac-
counted for 15% of the total variation of fibrinogen.
Other authors (33) found that 51% of the variance
of plasma fibrinogen concentration was accounted for
by genetic heritability. Iso et al. (34) found also that
mean plasma fibrinogen concentrations are 16% to
30% lower in Japanese men than in Caucasian men
(p < 0.001). This lower plasma fibrinogen concentra-
tion may be partially attributable to differences in
environmental factors. Diet, in particular, seems to
affect fibrinogen concentrations considerably. For ex-
ample, supplementation with fish oil and corn oil
(ω — 3 and ω — 6 polyunsaturated fatty acids) for 8
weeks is associated with 10% to 13% reductions of
plasma fibrinogen concentrations (p < 0.01) in pa-
tients with hyperlipoproteinaemia types lib or IV.
Such supplementation, particularly with fish oil,
therefore seems to have a beneficial "antithrombotic"
effect (35). Kromhout et al. (36) observed an inverse
dose-response relation between fish consumption and
death from coronary heart disease during 20 years
follow-up in a group of Dutchmen.
The fibrinogen concentration also varies seasonally.
It is up to 7% higher in summer (3.85 and 3.91 g/1 in
July and August, respectively) than in winter (3.65 g/1
in January) in healthy male blood donors (38).
Noise, infrasounds, vibrations and electromagnetic
fields all affect plasma fibrinogen concentrations.
Healthy men exposed to intense infrasounds, acoustic
noise and airborne dust during 2 to 15 years for 6 —8
hours per day, had 31% higher plasma fibrinogen
concentrations than control men of the same age (39).
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Other authors (40) found that plasma fibrinogen con-
centrations were 15% higher in men in lower grades
of employment than in those in higher grades (means
3.39 g/1 and 2.95 g/1, respectively; p < 0.01) but did
not find such differences in other haemostatic varia-
bles.
Plasma fibrinogen is subject to distinct physiological
variations but also to pathological variations during
the acute phase of the inflammatory reaction, diabe-
tes, malignant diseases and cardiovascular diseases.
In the acute-phase reaction, the plasma fibrinogen
concentration is at least 50% higher than normal.
After the tissular aggression, it increases slowly, show-
ing an appreciable change after 24 hours, in contrast
to C-reactive protein, which evolves rapidly (6 hours)
(41). Some drugs can also alter its concentration.
Pentoxifylline (Torental 400®) given to patients with
vascular disease or those with a high risk of throm-
bosis (due to diabetes or arteritis) significantly lowers
plasma fibrinogen concentrations (by 18% to 20%)
after a month of treatment (42, 43). The same effect
is obtained with bezafibrate (BefizalR) in patients with
insulin-dependent diabetes (44), in whom a 20% de-
crease is observed after the first month of treatment,
as well as a decrease of cholesterol and triacylglycer-
ols.
In this report we show that carefully defined reference
limits are needed for the interpretation of plasma
fibrinogen concentrations. Data from the literature
and our own results clearly show that these limits
must be improved. Analytical and preanalytical fac-
tors must be minimized by standardization of blood
sampling (exclusively on citrate; clotted, haemolysed
or lipaemic blood specimens should be discarded). If
samples cannot be analysed within 4 hours of collec-
tion, citrated plasma must be frozen and stored at
— 20 °C. Analytical variation must also be decreased
by using automatic analysers and performing all tests
at 37 + 1 °C. Finally, the following important bio-
logical factors must be taken into account: age, sex,
ponderal index, hormonal status (menopause), blood
pressure, pregnancy, alcohol and smoking habits, oral
contraceptive or drug intake and genetic and cultural
inheritance.
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